Published in Urology on October 01, 1999
Critical review of prostate cancer predictive tools. Future Oncol (2009) 1.57
Development and validation of a nomogram predicting the outcome of prostate biopsy based on patient age, digital rectal examination and serum prostate specific antigen. J Urol (2005) 1.45
Predicting the outcome of prostate biopsy: comparison of a novel logistic regression-based model, the prostate cancer risk calculator, and prostate-specific antigen level alone. BJU Int (2008) 1.17
Using biopsy to detect prostate cancer. Rev Urol (2008) 1.00
Discovery and validation of urinary biomarkers for prostate cancer. Proteomics Clin Appl (2008) 1.00
Predictive models for newly diagnosed prostate cancer patients. Rev Urol (2009) 0.89
Image-based clinical decision support for transrectal ultrasound in the diagnosis of prostate cancer: comparison of multiple logistic regression, artificial neural network, and support vector machine. Eur Radiol (2009) 0.89
Nomogram for prediction of prostate cancer with serum prostate specific antigen less than 10 ng/mL. J Korean Med Sci (2014) 0.86
Evaluation of the Prostate Cancer Prevention Trial Risk calculator in a high-risk screening population. BJU Int (2009) 0.85
African American men with low-grade prostate cancer have increased disease recurrence after prostatectomy compared with Caucasian men. Urol Oncol (2014) 0.84
Nomograms for colorectal cancer: A systematic review. World J Gastroenterol (2015) 0.82
Chinese nomogram to predict probability of positive initial prostate biopsy: a study in Taiwan region. Asian J Androl (2013) 0.82
A risk prediction model for smoking experimentation in Mexican American youth. Cancer Epidemiol Biomarkers Prev (2014) 0.78
External validation of an artificial neural network and two nomograms for prostate cancer detection. ISRN Urol (2012) 0.76
A prostate biopsy strategy based on a new clinical nomogram reduces the number of biopsy cores required in high-risk patients. BMC Urol (2014) 0.75
Independent validation of six melanoma risk prediction models. J Invest Dermatol (2014) 0.75
Developing a new score system for patients with PSA ranging from 4 to 20 ng/mL to improve the accuracy of PCa detection. Springerplus (2016) 0.75
Algorithms, nomograms and the detection of indolent prostate cancer. World J Urol (2008) 0.75
Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med (2013) 13.90
Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol (1999) 9.22
Relation between literacy, race, and stage of presentation among low-income patients with prostate cancer. J Clin Oncol (1998) 3.38
Long-term outcome among men with conservatively treated localised prostate cancer. Br J Cancer (2006) 2.76
The prognostic value of kidney transplant center report cards. Am J Transplant (2013) 2.64
Determining the area under the ROC curve for a binary diagnostic test. Med Decis Making (2001) 2.54
Factors predicting recovery of erections after radical prostatectomy. J Urol (2000) 2.44
Risk factors for urinary incontinence after radical prostatectomy. J Urol (1996) 2.42
Prediction of indolent prostate cancer: validation and updating of a prognostic nomogram. J Urol (2007) 2.26
Prognostic significance of positive surgical margins in radical prostatectomy specimens. J Urol (1995) 2.19
Androgen-independent prostate cancer progression in the TRAMP model. Cancer Res (1997) 2.16
More is not always better: a case for low-dose leucovorin. J Clin Oncol (1993) 2.03
Elevated levels of circulating interleukin-6 and transforming growth factor-beta1 in patients with metastatic prostatic carcinoma. J Urol (1999) 2.00
Elevated expression of caveolin is associated with prostate and breast cancer. Clin Cancer Res (1998) 1.95
Ki-67 and outcome in clinically localised prostate cancer: analysis of conservatively treated prostate cancer patients from the Trans-Atlantic Prostate Group study. Br J Cancer (2009) 1.77
Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasis. Urology (2001) 1.65
A calcitriol analogue, EB1089, inhibits the growth of LNCaP tumors in nude mice. Cancer Res (2000) 1.64
Prostate specific antigen decline following the discontinuation of flutamide in patients with stage D2 prostate cancer. Am J Med (1995) 1.60
cAMP-responsive element-binding protein regulates vascular endothelial growth factor expression: implication in human prostate cancer bone metastasis. Oncogene (2007) 1.58
Preoperative plasma levels of transforming growth factor beta(1) (TGF-beta(1)) strongly predict progression in patients undergoing radical prostatectomy. J Clin Oncol (2001) 1.55
Pathological features and prognostic significance of prostate cancer in the apical section determined by whole mount histology. J Urol (1999) 1.54
A catalog of prostate cancer nomograms. J Urol (2001) 1.51
Terminal neuroendocrine differentiation of human prostate carcinoma cells in response to increased intracellular cyclic AMP. Proc Natl Acad Sci U S A (1994) 1.44
Prediction of response to salvage radiation therapy in patients with prostate cancer recurrence after radical prostatectomy. J Clin Oncol (2001) 1.42
Vasopressin inhibits diuresis induced by water immersion in humans. J Appl Physiol (1985) (1992) 1.42
Hazard rates for progression after radical prostatectomy for clinically localized prostate cancer. Urology (1997) 1.41
Translation regulatory factor RBM3 is a proto-oncogene that prevents mitotic catastrophe. Oncogene (2008) 1.37
Short term preservation of porcine livers. J Surg Res (1970) 1.34
Validation of Partin tables for predicting pathological stage of clinically localized prostate cancer. J Urol (2000) 1.33
CD44-deficient mice exhibit enhanced hepatitis after concanavalin A injection: evidence for involvement of CD44 in activation-induced cell death. J Immunol (2001) 1.30
The danger of applying group-level utilities in decision analyses of the treatment of localized prostate cancer in individual patients. Med Decis Making (1999) 1.28
A phase I study of an anti-CD22-deglycosylated ricin A chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy. Blood (1993) 1.27
Distinguishing clinically important from unimportant prostate cancers before treatment: value of systematic biopsies. J Urol (1996) 1.26
Phase I immunotoxin trial in patients with B-cell lymphoma. Cancer Res (1991) 1.26
Clinical and pathological significance of the level and extent of capsular invasion in clinical stage T1-2 prostate cancer. Hum Pathol (1998) 1.26
New sources and instrumentation for neutrons in biology. Chem Phys (2008) 1.24
Has there been a recent shift in the pathological features and prognosis of patients treated with radical prostatectomy? J Urol (1997) 1.24
Prognostic significance of the diameter of perineural invasion in radical prostatectomy specimens. Hum Pathol (2001) 1.22
Long-term renal responses to high dietary protein in dogs with 75% nephrectomy. Kidney Int (1986) 1.21
Potency after permanent prostate brachytherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys (2001) 1.21
Management of prostate-specific antigen relapse in prostate cancer: a European Consensus. Int J Clin Pract (2004) 1.20
A critique of the decision analysis for clinically localized prostate cancer. J Urol (1994) 1.20
Impact of a clinical pathway for radical retropubic prostatectomy. Urology (1998) 1.20
Desmin-containing stellate cells in rat liver; distribution in normal animals and response to experimental acute liver injury. J Pathol (1986) 1.19
Non-thermal irreversible electroporation (N-TIRE) and adjuvant fractionated radiotherapeutic multimodal therapy for intracranial malignant glioma in a canine patient. Technol Cancer Res Treat (2011) 1.16
Disease recurrence in black and white men undergoing radical prostatectomy for clinical stage T1-T2 prostate cancer. J Urol (2000) 1.16
E-cadherin immunostaining of bladder transitional cell carcinoma, carcinoma in situ and lymph node metastases with long-term followup. J Urol (2001) 1.15
Preoperative plasma levels of transforming growth factor beta(1) strongly predict clinical outcome in patients with bladder carcinoma. Cancer (2001) 1.14
Height and lymphoblastic leukaemia. Arch Dis Child (1983) 1.14
Prostate-specific antigen (PSA) and PSA density: racial differences in men without prostate cancer. J Natl Cancer Inst (1997) 1.14
Salt-dependent DNA superhelix diameter studied by small angle neutron scattering measurements and Monte Carlo simulations. Biophys J (1998) 1.13
Assessment of the biologic markers p53, Ki-67, and apoptotic index as predictive indicators of prostate carcinoma recurrence after surgery. Cancer (1998) 1.13
Critical evaluation of the modified-adult immersion test with discriminating dose bioassay for Boophilus microplus using American and Australian isolates. Vet Parasitol (2007) 1.12
Alteration of the phosphorylation state of p34cdc2 kinase by the flavone L86-8275 in breast carcinoma cells. Correlation with decreased H1 kinase activity. Biochem Pharmacol (1993) 1.11
Outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation (RISCT) using antilymphocyte antibodies in patients with high-risk acute myeloid leukemia (AML). Bone Marrow Transplant (2006) 1.10
Incidence, location, and significance of periprostatic and periseminal vesicle lymph nodes in prostate cancer. Am J Surg Pathol (2001) 1.10
The subunit positions within RNA polymerase holoenzyme determined by triangulation of centre-to-centre distances. Eur J Biochem (1980) 1.08
Combined androgen blockade with nonsteroidal antiandrogens for advanced prostate cancer: a systematic review. Urology (2001) 1.06
A comparison of bifonazole (BAY H 4502) with clotrimazole in vitro. Sabouraudia (1982) 1.05
Spontaneous systemic hypertension in dogs: five cases (1981-1983). J Am Vet Med Assoc (1988) 1.05
Increase in overall mortality risk in patients with type 2 diabetes receiving glipizide, glyburide or glimepiride monotherapy versus metformin: a retrospective analysis. Diabetes Obes Metab (2012) 1.05
Juvenile hereditary polyglucosan body disease with complete branching enzyme deficiency (type IV glycogenosis). Acta Neuropathol (1993) 1.04
Fifteen-year survival and recurrence rates after radiotherapy for localized prostate cancer. J Clin Oncol (1997) 1.03
Pathologic findings in the stomachs of rats treated with the H2-receptor antagonist tiotidine. Scand J Gastroenterol Suppl (1984) 1.03
Primary Gleason pattern as a predictor of disease progression in gleason score 7 prostate cancer: a multivariate analysis of 823 men treated with radical prostatectomy. Am J Surg Pathol (2001) 1.03
Purine nucleoside phosphorylase from Salmonella typhimurium and rat liver. Methods Enzymol (1978) 1.03
Drug-induced apoptosis is not necessarily dependent on macromolecular synthesis or proliferation in the p53-negative human prostate cancer cell line PC-3. Cancer Res (1995) 1.02
Mast cells express IL-13R alpha 1: IL-13 promotes human lung mast cell proliferation and Fc epsilon RI expression. Allergy (2006) 1.02
[Problems of phlebopathology with special reference to phlebosclerosis]. Zentralbl Phlebol (1967) 1.01
Changing face and different countenances of prostate cancer: racial and geographic differences in prostate-specific antigen (PSA), stage, and grade trends in the PSA era. Int J Cancer (2001) 1.01
Risk factors for complications and morbidity after radical retropubic prostatectomy. J Urol (1997) 1.00
Enhanced ordering temperatures in antiferromagnetic manganite superlattices. Nat Mater (2009) 1.00
Recall and attitudes in patients with prostate cancer. Urology (1999) 1.00
A pilot study of interferon alfa-2a in combination with fluorouracil plus high-dose leucovorin in metastatic gastrointestinal carcinoma. J Clin Oncol (1991) 1.00
Assessing quality of life in men with clinically localized prostate cancer: development of a new instrument for use in multiple settings. Qual Life Res (2000) 0.96
Perineurial cells are the first to traverse gaps of peripheral nerves in silicone tubes. Clin Neurol Neurosurg (1993) 0.95
Antitumor activity of suramin in hormone-refractory prostate cancer controlling for hydrocortisone treatment and flutamide withdrawal as potentially confounding variables. Cancer (1995) 0.95
Clinical characteristics and biopsy specimen features in African-American and white men without prostate cancer. J Natl Cancer Inst (1998) 0.94
Machine learning for survival analysis: a case study on recurrence of prostate cancer. Artif Intell Med (2000) 0.94
New trends in glass-ionomer chemistry. Biomaterials (1998) 0.94
A national survey of attitudes regarding participation in prostate carcinoma testing. Cancer (1996) 0.93
Defining high risk prostate cancer with risk groups and nomograms: implications for designing clinical trials. J Urol (2006) 0.92
Characterization of two epiphytic bacteria from soybean leaves with antagonistic activities against Pseudomonas syringae pv. glycinea. J Basic Microbiol (1996) 0.92
Complexity, fractals, disease time, and cancer. Phys Rev E Stat Nonlin Soft Matter Phys (2004) 0.92
Postatrophic hyperplasia of the prostate: lack of association with prostate cancer. Am J Surg Pathol (1999) 0.92
Nomograms for predicting graft function and survival in living donor kidney transplantation based on the UNOS Registry. J Urol (2009) 0.92
Potassium channel openers depolarize hippocampal mitochondria. Brain Res (2001) 0.91
A phase I/II study of continuous infusion suramin in patients with hormone-refractory prostate cancer: toxicity and response. Cancer Chemother Pharmacol (1996) 0.91
Levels of expression of p27KIP1 protein in human prostate and prostate cancer: an immunohistochemical analysis. Mod Pathol (1999) 0.91
Perineural invasion of prostate carcinoma cells is associated with reduced apoptotic index. Cancer (1996) 0.90
The effect of temperature and water quality on antibody response to Aeromonas salmonicida in sunshine bass (Morone chrysops x Morone saxatilis). Vet Immunol Immunopathol (1996) 0.90
Lymphovascular invasion as a predictor of disease progression in prostate cancer. Am J Surg Pathol (2000) 0.90
Primary human prostate cancer cells harboring p53 mutations are clonally expanded in metastases. Clin Cancer Res (1997) 0.90
Pitfalls in the diagnosis of prostatic cancer: retrospective review of 1791 cases with clinical outcome. Histopathology (2007) 0.89
Investigation of glomerular lesions in dogs with acute experimentally induced Ehrlichia canis infection. Am J Vet Res (1992) 0.88
Alterations in the expression of pp60c-src and p56lck associated with butyrate-induced differentiation of human colon carcinoma cells. Oncogene Res (1989) 0.88
[Aneurysms of the popliteal vein]. Fortschr Geb Rontgenstr Nuklearmed (1968) 0.87
Renal dysfunction in dogs with pyometra. J Am Vet Med Assoc (1988) 0.87